REMDESIVIR DOES NOT SAVE LIVES, DECREASES RECOVERY BY ONLY 4 DAYS, FUNDED BY U.S. TAXPAYERS
The U.S. taxpayer played the major role in funding the discovery of remdesivir and its use in treating coronaviruses.
Now the U.S. taxpayer is being told to pay $3,120 for five doses of remdesivir to decrease recovery time by a mere four days for hospitalized COVID-19 patients.
